Literature DB >> 7352754

In vitro studies of 1-oxacephalosporin (LY 127935), a new beta-lactam antibiotic.

S S Weaver, B M LeBlanc, G P Bodey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7352754      PMCID： PMC283733          DOI： 10.1128/AAC.17.1.92

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  5 in total

1.  Resistance of gram-negative bacilli to gentamicin.

Authors:  C F Snelling; A R Ronald; C Y Cates; W C Forsythe
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

2.  Amikacin therapy of severe infections produced by gram-negative bacilli resistant to gentamicin.

Authors:  M Valdivieso; G P Bodey
Journal:  Am J Med Sci       Date:  1977 Mar-Apr       Impact factor: 2.378

3.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

4.  BL-S786 (ceforanide), a new parenteral cephalosporin: in vitro studies.

Authors:  S S Weaver; B M LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

5.  HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria.

Authors:  H C Neu; N Aswapokee; P Aswapokee; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191
  5 in total
  12 in total

Review 1.  The third generation cephalosporins.

Authors:  B Farber; R C Moellering
Journal:  Bull N Y Acad Med       Date:  1982-11

2.  Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae.

Authors:  T H Brown; R H Alford
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

3.  Comparative susceptibilities of clinical isolates of Serratia marcescens to newer cephalosporins, alone and in combination with various aminoglycosides.

Authors:  S M Markowitz; D J Sibilla
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

4.  Comparative in vitro study in new cephalosporins.

Authors:  G P Bodey; V Fainstein; A M Hinkle
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

5.  [N-formimidoyl-thienamycin: in vitro activity in bacteria with resistance to beta-lactam antibiotics or gentamicin].

Authors:  K Bartmann; R Tarbuc
Journal:  Infection       Date:  1982 Nov-Dec       Impact factor: 3.553

6.  Clinical evaluation of moxalactam: evidence of decreased efficacy in gram-positive aerobic infections.

Authors:  W Salzer; P S Pegram; C E McCall
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

7.  Moxalactam therapy of bacterial meningitis in adults.

Authors:  M Uwaydah; N Tannir; H Kantarjian; M Osseiran; F Bal'a
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

Review 8.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

9.  Randomized comparative study of moxalactam and cefazolin in the treatment of acute urinary tract infections in adults.

Authors:  A S Lea; A W Sudan; B A Wood; L O Gentry
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

10.  Moxalactam in the therapy of serious infections.

Authors:  R L Marier; S Faro; C V Sanders; W Williams; F Derks; A Janney; K Aldridge
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.